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a b s t r a c t 
Bleomycin electrochemotherapy (ECT) has emerged as a treatment 
modality for locally advanced metastatic melanoma over the past 
decade. The phenomenon of reversible electroporation enhances 
cell permeability when a pulsed electrical current is applied to tis- 
sues. This facilitates enhanced cytotoxicity of bleomycin with min- 
imal systemic side effects. 
We present two case analyses of patients with advanced metastatic 
melanoma of lower limb which did not respond to alternative ther- 
apies, including immunotherapy and isolated limb perfusion, but 
had a positive clinical response to bleomycin ECT. Locoregional con- 
trol of the tumour was gained along with positive functional out- 
comes for the patients including increased mobility and reduced 
malodour. 
Bleomycin ECT is an exciting new therapeutic modality in the ar- 
mamentarium of the plastic surgeon. Operating parameters have 
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been developed and refined which facilitate its safe use along with 
incorporation into international melanoma guidelines. Evidence in 
the literature supports its use in select cases, however, it is vital 
that we share our experiences in its use so that its role can be bet- 
ter defined. Particularly in the era of rapidly developing systemic 
treatments which are decreasing mortality and thereby increasing 
the number of patients requiring locoregional disease managment. 
© 2020 The Authors. Published by Elsevier Ltd on behalf of British 
Association of Plastic, Reconstructive and Aesthetic Surgeons. 
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m  ntroduction 
Melanoma Bleomycin electrochemotherapy (ECT) has emerged as a treatment modality for locally
dvanced metastatic melanoma over the past decade. The phenomenon of reversible electroporation
nhances cell permeability when a pulsed electrical current is applied to tissues. 1 , 2 This facilitates
reater local cytotoxicity of chemotherapeutic agents such as Bleomycin, whilst reducing systemic side
ffects due to the lower systemic dose required. Indeed, the cytotoxicity of bleomycin is enhanced up
o 700-fold in combination with reversible electroporation technology. 2 Bleomycin ECT is predomi-
antly indicated for accessible neoplastic lesions including palliative management of locally advanced
etastatic melanoma. 1 , 3 Despite this, many melanoma surgeons are still unfamiliar with this treat-
ent modality and it is likely underutilised. 
In this report we discuss our bleomycin ECT treatment regime and care pathway in the context
f this new era of targeted therapy (TT) and immuno-therapy (IT). We present two case analyses
f patients with advanced metastatic melanoma of lower limb where options for standard therapies,
ncluding isolated limb perfusion, had been exhausted but in which a dramatic clinical response to
leomycin ECT was observed. 
ase report 
The device used for both cases was the Cliniporator TM (IGEA Clinical Biophysics, Italy), with a cen-
red hexagonal needle electrode, and was used in concordance with published guidelines. 4 
ase 1 
A 70-year-old woman with no other significant medical co-morbidities or regular medications was
iagnosed with a 15 mm Breslow thickness left foot acral malignant melanoma (BRAF wild type). She
ad wide excision and a sentinel lymph node biopsy (SLNB) was positive. She declined groin dissec-
ion (preceded adjuvant therapy availability). A year later recurrent disease was identified on positron
mission tomography (PET) in the popliteal fossa lymph nodes and adjacent to the graft site on the
ole of the foot. She had six cycles of pembrolizumab followed by T-VEC (Talimogene laherparepvec
ncolytic virus) and isolated limb perfusion (ILP) over the following year. In-transit metastases and
esions on her leg significantly impacted her quality of life with pain, bleeding and resultant reduced
obility. Whilst ILP did reduce the size of some of the lesions her symptoms did not improve sig-
ificantly, and she was referred for consideration of ECT. She had debulking and bleomycin ECT to
er extensive lesions with 171 sequences completed in total (see Table 1 ). The treatment resulted in
onsiderable reduction in tumour mass with less bleeding and less painful mobilization with partial
eight bearing on crutches ( Figure 1 ). She had increased pain and wound care requirements for a
eriod of several months following bleomycin ECT. She had a further round of bleomycin ECT five
onths later with good effect and remained independent in activities of daily living. Post-treatment44 
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Table 1 
Bleomycin electrochemotherapy delivery. 
Probe Configuration Frequency (kilohertz, kHz) Sequences ( n ) Duration (min) 
Case 1 Hexagonal 5 kHz Total: 171 39 min 
Case 2 Hexagonal 5 kHz Total: 95 12 min 
















m  ain recurred following the second round of bleomycin ECT and was managed with oral analgesia
lone. 
ase 2 
A 51-year-old gentleman with a background of coeliac disease was diagnosed with malignant
elanoma (BRAF wild type) of the right calf. Wide excision was carried out. Six years later the
isease recurred with regional lymph node involvement and local disease recurrence. He received
mmunotherapy (7 doses of nivolumab) and, following a groin dissection, this was changed to ipil-
mumab. A single cycle induced auto-immune meningitis which necessitated cessation of treatment
nd a protracted course of prednisolone. Cutaneous and subcutaneous recurrences were initially surgi-
ally excised. T-VEC therapy had a limited effect on local disease and he was referred for ECT. His main
omplaint was the size and growth of a single metastasis lateral to his knee. The malodour was dis-
bling, its size prevented wearing trousers and he was experiencing significant pain requiring opioid
nalgesics (dihydrocodeine). He had debulking and bleomycin ECT, completing 95 sequences in total
see Table 1 ). The bleomycin ECT treatment was successful in reducing and maintaining the reduction
n tumour bulk (Figure 2) . Following bleomycin ECT the patient was able to wear trousers and the
alodorous smell had resolved. There was increased pain following bleomycin ECT, however, at four45 
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Figure 2. Case 2. Left knee, medial aspect. (A) Pre-operative. (B) 1-month post-operative. (C) 3-months post-operative (proximal 
tumour recurrence subsequently treated with excision). 
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onths this significantly reduced. Of note, the patient developed common peroneal nerve palsy, 3/5
ower (NRC scale), improving to 4/5 power which may have been due to bleomycin ECT or tumour
nvasion. 
iscussion 
Management of locally advanced metastatic melanoma is challenging with a plethora of available
reatment modalities including excisional and ablative surgery, systemic therapies, ILP, radiotherapy
nd ECT. 3 Systemic therapies (TT and IT) are rapidly evolving and increasingly available, they signifi-
antly prolong the course of the disease, are potentially curative and increase the number of patients
ho may benefit from local disease management. 5 
Bleomycin ECT is now recognised as a safe treatment for cutaneous tumours and skin metastases
ith established standard operating procedures. 4 This is evidenced by its incorporation into clinical
uidelines internationally. 3 , 6 , 7 The evidence base is growing and a recently published cohort study
f by the InspECT research group including 394 melanoma lesions found that 78% (306) had a com-
lete or partial response, and 58% (229) had a complete response to bleomycin ECT. 8 Additionally,
here is emerging evidence that bleomycin ECT may be particularly effective in combination with im-
unotherapies, acting synergistically and producing enhanced systemic anti-tumour effects (the ‘ab-
copal effect’). 9 , 10 This is of particular importance to patients, such as those in this report, with a
wild-type’ BRAF gene precluding the use of TT to the BRAF and MEK pathway. These patients cannot
enefit from the highly effective TT combination of BRAF and MEK inhibitors. 5 Post-treatment pain is
 recognised complication of bleomycin ECT, has a reported incidence of 39% and is manageable with
ral analgesia in the majority of cases. 8 
Clinicians determine on a case-by-case basis, or regional availability of services, which local pe-
ipheral treatments are used. National and international guidelines do not currently specify an algo-
ithmic approach to determine which modality should be considered first-line. 3 , 7 This approach ap-
ropriately reflects the paucity of comparative studies evaluating peripheral treatment modalities for
ocally advanced metastatic melanoma. 10 We have presented two cases with a dramatic response to
lectrochemotherapy resulting in improved symptoms and quality of life. In both cases bleomycin ECT
as considered after other modalities were utilised based on local dogmatic practice in which ILP is
enerally first-line. 
onclusions 
These cases highlight the clinical efficacy of bleomycin ECT in managing locally advanced
etastatic melanoma in the context of a new era of systemic therapies and improved survival. More
esearch, in particular comparative studies, are required to establish the relative efficacy of bleomycin
CT versus other modalities. As the evidence base evolves guidelines must be regularly updated to en-
ure that clinicians are aware of the options available for their patients and their efficacy. Additionally,
f modalities are clinically non-inferior cost-effectiveness analysis is warranted. 
















1  eferences 
1. Probst U , Fuhrmann I , Beyer L , Wiggermann P . Electrochemotherapy as a new modality in interventional oncology: a review.
Technol Cancer Res Treat . 2018;17 1533033818785329 . 
2. Mir LM , Orlowski S , Belehradek Jr J , Paoletti C . Electrochemotherapy potentiation of antitumour effect of bleomycin by local
electric pulses. Eur J Cancer . 1991;27:68–72 . 
3. National Institute for Health and Care Excellence Melanoma: assessment and management https://www.nice.org.uk/
guidance/ng14/chapter/1- Recommendations#managing- stage- iv- melanoma (Accessed 01/03/2020). 
4. Gehl J , Sersa G , Matthiessen LW , et al. Updated standard operating procedures for electrochemotherapy of cutaneous tu-
mours and skin metastases. Acta Oncol . 2018;57:874–882 . 
5. Pasquali S , Hadjinicolaou AV , Chiarion Sileni V , Rossi CR , Mocellin S . Systemic treatments for metastatic cutaneous
melanoma. Cochrane Database Syst Rev . 2018;2 . 
6. National Institute for Health and Care Excellence Electrochemotherapy for metastases in the skin from tumours of non-skin
origin and melanoma https://www.nice.org.uk/guidance/IPG446 (Accessed 01/05/2020). 
7. Garbe C , Amaral T , Peris K , et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment –
update 2019. Eur J Cancer . 2020;126:159–177 . 
8. Kunte C , Letule V , Gehl J , et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective
cohort study by InspECT. Br J Dermatol . 2017;176:1475–1485 . 
9. Goggins CA , Khachemoune A . The use of electrochemotherapy in combination with immunotherapy in the treatment of
metastatic melanoma: a focused review. Int J Dermatol . 2019;58:865–870 . 
0. Read RL , Thompson JF . Managing in-transit melanoma metastases in the new era of effective systemic therapies for
melanoma. Expert Rev Clin Pharmacol . 2019;12:1107–1119 . 48 
